InnoCare Pharma eyes Hong Kong listing
Chinese firm InnoCare Pharma is looking for permission to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.
The company has hired Goldman Sachs and Morgan Stanley as the joint sponsors of the listing.InnoCare is a clinical stage biopharmaceutical company focused on treatments for cancer and autoimmune diseases. It is working on three cancer drug candidates and a handful related to autoimmune diseases, according to ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org